Zhang, H;
Deng, M;
Pei, F;
Wang, S;
Ho, M;
(2019)
Next-Generation Antibody Therapeutics: Discovery, Development and Beyond: highlights of the third annual conference of the Chinese Antibody Society.
Antibody Therapeutics
, 2
(4)
pp. 99-107.
10.1093/abt/tbz012.
Preview |
Text
tbz012.pdf - Published Version Download (1MB) | Preview |
Abstract
The Chinese Antibody Society (CAS) convened the third annual conference in Cambridge, Massachusetts, USA on April 7, 2019. More than 600 global members attended the meeting. The theme of this conference was Next-Generation Antibody Therapeutics: Discovery, Development and Beyond. The meeting covered a vast variety of topics including cancer immunotherapy, single-domain antibodies as well as bispecific antibodies, immunotoxins, transgenic mouse platforms for next-generation monoclonal antibody discovery and antibody chemistry, manufacturing and controls (CMCs). Two hot topics were comprehensively discussed by the prestigious panelists and hosts at the panel discussions during the conferences, i.e., bispecific antibodies and antibody CMC.
| Type: | Article |
|---|---|
| Title: | Next-Generation Antibody Therapeutics: Discovery, Development and Beyond: highlights of the third annual conference of the Chinese Antibody Society |
| Location: | United States |
| Open access status: | An open access version is available from UCL Discovery |
| DOI: | 10.1093/abt/tbz012 |
| Publisher version: | http://dx.doi.org/10.1093/abt/tbz012 |
| Language: | English |
| Additional information: | © The Author(s) 2019. Published by Oxford University Press on behalf of Antibody Therapeutics. This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/bync/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
| Keywords: | Chinese Antibody Society, antibody therapeutics, bispecific antibodies, chemistry manufacturing and Controls (CMC), immuno-oncology, immunotoxin, single-domain antibody, transgenic mouse platforms |
| UCL classification: | UCL UCL > Provost and Vice Provost Offices > UCL BEAMS UCL > Provost and Vice Provost Offices > UCL BEAMS > Faculty of Engineering Science UCL > Provost and Vice Provost Offices > UCL BEAMS > Faculty of Engineering Science > Dept of Biochemical Engineering |
| URI: | https://discovery.ucl.ac.uk/id/eprint/10127751 |
Archive Staff Only
 |
View Item |
